ABSTRACT:
Aim: The objective of the present study was to develop an immediate release tablet of Dasatinib using different concentration of superdisintegrants with a view to obtain rapid action for myelogenous leukemia and acute lymphoblastic leukemia[1]. Dasatinib is a chemotherapy medication used to treat certain cases of leukaemia. Materials and Methods: Various formulations were prepared by direct compression technique using super disintegrants (cross carmellose sodium, sodium starch glyclote and crospovidone). Effect of different superdisintegrants on drug release was studied. Optimized formulation was selected on the basis of drug release and its in-vitro release profile compared with the reference product (Sprycel). Results and Discussion: The dissolution results showed gradient increase in the drug release with the increase in concentration of the super-disintegrants. Conclusion: Among all the formulations F3 containing croscarmellose sodium (4.5%) was found to show best results with 98.3% release within 45 minutes and it exhibited a release profile comparable to the reference product.